T.R. Jeffry Evans
YOU?
Author Swipe
View article: Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis Open
Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlli…
View article: Supplementary Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Supplementary Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study Open
Supplementary appendix, supplementary tables s1 - s9, supplementary figures s1 - s8
View article: Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response Open
Pancreatic ductal adenocarcinoma (PDAC) is characterized by increasing fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrisome of the highly metastatic KPC ( Pdx1-Cre , …
View article: A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma Open
SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel. No improvement in OS was observed, and the modest improvement in PFS is not practice changing.
View article: Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT Open
Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs. 12.3 months; HR 0.92, 95% CI 0.79–1.06). The objective respon…
View article: Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study
Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study Open
Objective The COVID-19 pandemic had an undoubted impact on the provision of elective and emergency cancer care, including the diagnosis and management of patients with hepatocellular carcinoma (HCC). Our aim was to determine the effects of…
View article: Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study Open
Background Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma. However, there is a high unmet need for patients who progress on these therapies and combination therapies are being explored to…
View article: Supplemental Tables 1 through 3 from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Supplemental Tables 1 through 3 from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer Open
Table S1: Antibodies for immunohistochemistry. Table S2: shRNA sequences. Table S3: Antibodies for western blotting.
View article: Data from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Data from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer Open
mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex. However, clinical trials of mTORC1 inhibitors…
View article: Supplementary Figure 1c from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Supplementary Figure 1c from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial Open
Supplementary Figure 1. Kaplan-Meier survival curves of treatment effect on TTP in patients with low (left panel) and high (right panel) baseline levels of (A) epiregulin (max chi interaction P value = 0.193), (B) VEGF-A (max chi interacti…
View article: Supplementary Materials from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Supplementary Materials from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors Open
Supplementary Materials. Table 1. Drug-related adverse events (AEs) occurring during the initial 21 days of dosing in the expansion cohorts Table 2. Plasma OSI-906 pharmacokinetic parameters (expansion cohorts, Days 1 and 22) Table 3. Dose…
View article: Supplementary Materials and Methods from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Materials and Methods from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
PDF file - 131K, Supplementary Results and Methods.
View article: Supplementary Table 9 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 9 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
XLS file - 168K, A. Combination of predicted targets for miRNAs associated with favourable prognosis (miR-29c, miR-30d, miR-34a). B. Combination of predicted targets for miRNAs associated with poor prognosis (miR-21, miR-221, miR-224).
View article: Supplementary Figure 1d from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Supplementary Figure 1d from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial Open
Supplementary Figure 1. Kaplan-Meier survival curves of treatment effect on TTP in patients with low (left panel) and high (right panel) baseline levels of (A) epiregulin (max chi interaction P value = 0.193), (B) VEGF-A (max chi interacti…
View article: Supplementary Materials and Methods from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Materials and Methods from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
PDF file - 131K, Supplementary Results and Methods.
View article: Supplemental Figure Legends from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Supplemental Figure Legends from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer Open
Supplementary figure legends for Figures S1-S8
View article: Supplementary Table 2 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 2 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
XLS file - 47K, Conventional clinicopathological factors in PDAC cohort (n = 48) associated with survival following resection based on multivariate analysis.
View article: Supplementary Tables and Figures TC from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Supplementary Tables and Figures TC from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial Open
Supplementary appendix: Includes 2 tables: (1) summary of analysis results for plasma biomarkers as predictive factors for treatment effect on overall survival; and (2) summary of analysis results for plasma biomarkers as predictive factor…
View article: Supplementary Table 1 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 1 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
XLS file - 48K, Conventional clinicopathological parameters in PDAC cohort (n = 48) univariately associated with survival following resection.
View article: Supplemental Figures 1 through 8 from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Supplemental Figures 1 through 8 from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer Open
Figure S1: Loss of Rictor does not prevent pancreatic formation or function. Figure S2: Rictor deletion decreases proliferation in PanIN1 lesions. Figure S3: Rictor deletion alters CDKI and BMI1 expression and localization. Figure S4: Rict…
View article: Data from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Data from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
Purpose: MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic targets in cancer. We sought to establish the relationship between miRNA expression and clinicopathologic parameters, including prognosis,…
View article: Supplementary Figure 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Figure 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
PDF file - 211K, Bioinformatics enrichment of miRNAs associated with poor outcome. A) Pathway enrichment of the targets of miR-21, miR-221, and miR-224 demonstrating union and intersections. B) Enrichment of TGF-� and C) MAPKinase KEGG pat…
View article: Supplementary Table 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
PDF file - 270K, Association of miRNA expression levels measured by RT-PCR with overall survival: univariate analysis.
View article: Supplementary Table 7 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 7 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
PDF file - 189K, Multivariate Cox regression analysis of association of PTEN and clinicopathological factors and overall survival.
View article: Supplementary Table 6 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 6 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
XLS file - 50K, Multivariate analysis of combined 72 patient cohort. A) All 72 patients. B) 38 patients with low miR-21 expression (less than median expression value). C) 34 patients with high miR-21 expression (greater than median express…
View article: Supplementary Table 9 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 9 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
XLS file - 168K, A. Combination of predicted targets for miRNAs associated with favourable prognosis (miR-29c, miR-30d, miR-34a). B. Combination of predicted targets for miRNAs associated with poor prognosis (miR-21, miR-221, miR-224).
View article: Supplementary Table 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
PDF file - 270K, Association of miRNA expression levels measured by RT-PCR with overall survival: univariate analysis.
View article: Supplementary Table 4 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 4 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
PDF file - 274K, Differentially expressed microRNAs normal pancreas versus PDAC.
View article: Supplementary Table 8 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Supplementary Table 8 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Open
XLS file - 433K, A. Gene expression according to miR-21 expression in 43 patients with PDAC. B. Gene expression according to miR-34a expression in 43 patients with PDAC.